Products

Biotherapies differ from conventional pharmaceuticals in that they treat diseases with products derived from human plasma or manufactured by recombinant technologies, while conventional pharmaceuticals derive their products from chemicals. Biotherapeutic proteins replace missing components in the blood.

CSL Behring develops, manufactures, and markets protein-based therapies in the Bleeding Disorders, Critical Care, Immunoglobulins, Pulmonary, and Wound Healing areas.

Learn more about:
		Bleeding Disorders Products >		Critical Care Products >
		Immunoglobulin Products >		Pulmonary Products >
		Wound Healing Products >

We are proud to serve unique communities of patients with von Willebrand disease, hemophilia, primary immunodeficiency, genetic emphysema, and other rare diseases. Our biotherapies can also prevent Rhesus-factor problems in newborns, and prevent or stop bleeding in emergencies or planned surgery.

CSL Behring is serious and passionate not just about saving lives, but about improving the quality of life for patients. Our products represent life-saving therapies and we are committed to working toward normalizing the life of patients.

Product availability varies from country to country, depending on registration status.

Please contact your CSL Behring representative.